



Lumos Pharma to Participate in Upcoming Investor Conferences

August 27, 2020

AUSTIN, Texas, Aug. 27, 2020 (GLOBE NEWSWIRE) -- [Lumos Pharma, Inc.](#) (NASDAQ:LUMO), a clinical-stage biopharmaceutical company focused on therapeutics for rare diseases, announced that the company will present and host one-on-one meetings at the following virtual investor conferences to be held in September:

• H. C. Wainwright 22nd Annual Global Investment Conference – September 14-16, 2020

- Lumos Pharma is scheduled to present Monday, September 14th, at 4:30PM ET
- Management will be available for virtual one-on-one meetings September 14th – 16th

• Cantor Virtual Global Healthcare Conference – September 15-17, 2020

- Lumos Pharma is scheduled to present Thursday, September 17th, at 8:40AM ET
- Management will be available for virtual one-on-one meetings September 17th throughout the day

Please contact your HC Wainwright and Cantor Fitzgerald sales representatives to participate in their investor conferences and to schedule a virtual one-on-one meeting with our management team.

Live webcasts of each presentation will be available on the Company's website in the "Investors & Media" section under "[Events and Presentations.](#)" An archived edition of the presentation will be available on the Company's website later in the day on each day Lumos Pharma presents.

About Lumos Pharma

Lumos Pharma, Inc. is a clinical stage biopharmaceutical company focused on the development and commercialization of therapeutics for rare diseases. Lumos Pharma was founded and is led by a management team with longstanding experience in rare disease drug development and received early funding by leading healthcare investors, including Deerfield Management, a fund managed by Blackstone Life Sciences, Roche Venture Fund, New Enterprise Associates (NEA), Santé Ventures, and UCB. Lumos Pharma's lead therapeutic candidate is LUM-201, an oral growth hormone stimulating small molecule for the treatment of Pediatric Growth Hormone Deficiency (PGHD). If approved by the FDA, LUM-201 would provide an orally administered alternative to daily injections that current PGHD patients endure for many years of treatment. LUM-201 has received Orphan Drug Designation in both the US and EU. For more information, please visit www.lumos-pharma.com.

Investor & Media Contact:

Lisa Miller
Lumos Pharma Investor Relations
512-648-3757
ir@lumos-pharma.com

Source: Lumos Pharma, Inc.



Source: Lumos Pharma, Inc.